DSM Q1 2017 Results

HEERLEN, The Netherlands, May 2, 2017 /PRNewswire/ --

Highlights

• DSM reports a very strong first quarter
• Sales up 13% to €2,159m, with 9% organic growth
• Adjusted EBITDA up 17% to €345m
• ROCE up 150 bps to 11.3%
• Cash from operating activities up 43% to €196m
• Net profit up 75% to €149m
• Outlook maintained

Key figures and indicators

   
    in EUR million      Q1 2017 Q1 2016 % Change Volume Price/mix   FX Other
    Sales                 2,159   1,913      13%     6%        3%   3%    1%
    Nutrition             1,398   1,250      12%     5%        3%   4%    0%
    Materials               701     600      17%    11%        3%   1%    2%
    Adjusted EBITDA         345     296      17%
    Nutrition               257     225      14%
    Materials               113      95      19%
    EBITDA                  334     271
    ROCE (%)              11.3%    9.8%

     (Logo: http://photos.prnewswire.com/prnh/20160803/395298LOGO )

CEO statement

Feike Sijbesma, CEO/Chairman of the DSM Managing Board, commented: "We are pleased to report a very good start to the year, with continued positive momentum in all businesses as we execute on our mid-term strategic and financial ambitions. Nutrition continued to deliver on its objectives with good growth from Animal and Human Nutrition. Materials demonstrated once again the benefit of its focus on specialties. Both businesses achieved strong volume growth, well above the market.

Notwithstanding the current global socio-economic volatility, we are confident that we will be able to deliver against our full-year objectives given our focus on improving our financial performance through our growth initiatives and our extensive and ambitious profit improvement programs. At the same time we continue to manage our business for the longer term by pursuing our innovation-driven growth strategy." 

Outlook 2017
DSM aims to deliver high-single digit percentage Adjusted EBITDA growth and high double-digit basis point ROCE growth in line with the targets set out in its Strategy 2018.

Note for the editors: for the full text of the press release see enclosed pdf or click here>

Financial calendar 

3 May 2017            Annual General Meeting of Shareholders

5 May 2017            Ex-dividend    

1 August    2017            Publication of Q2 2017 Results

2 November 2017            Publication of Q3 2017 Results

14 February 2018            Publication of Q4 2017 Results

Additional Information 

Today DSM will hold a conference call for media at 08:00 and a conference call for investors and analysts at 09:00. Details on how to access these calls can be found on the DSM website, http://www.dsm.com.

DSM - Bright Science. Brighter Living.™  

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in life sciences and materials sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at http://www.dsm.com.

Forward Looking Statement 

This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law.

Contact Information
Investor Relations
Dave Huizing
t. +31(0)45-578-28-64
e. [email protected]

Media Relations
Stephen Hufton
t. +31(0)45-578-7029
e. [email protected]

PRN NLD